• Bertz R.J., Granneman G.R., 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interaction. Clin. Pharmacokinetic. Vol.

(1)

• Anandatheerthavarada H.K., Shankar S.K., Bhamre S., Boyd M.R., Song B.J., Ravindranath V., 1993. Induction of brain cytochrome P4502E1 by chronic ethanol treatment. Brain Res. Vol 601, pp 279-285.

• Bachurin S.O., Shevtzova E.P., Lermontova N.N., Serkova T.P., Ramsay R.R., 1996. The effect of dithiocarbamates on neurotoxic action of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) and on mitochondrial respiration chain. Neurotoxicology Vol. 17, pp 897-904.

• Bertz R.J., Granneman G.R., 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interaction. Clin. Pharmacokinetic. Vol.

32, pp 210-258.

• Blum D., Torch S., Lambeng N., Nissou M.F., Banabid A.L., Sadoul R., Verna J.M., 2001. Molecular patways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apopotic theory in Parkinson’s desease. Progress in Neurobiology Vol. 65, pp 135-172.

• Brady J.F., Ishizaki H., Fukuto J.M., Lin M.C., Fadel A.,

Gapac J.M., Yang C.S., 1991. Inhibition of cytocrome P-

450 2E1 by diallyl sulphide and its metabolites. Chem.

(2)

• Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J., 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl.

Acad. Sci. USA Vol. 80, pp 4546-4550.

• Cassee F.R., Groton J.P., Van Bladeren P.J., Feron V.J., 1998. Toxicology of chemical mixtures: international perspective. Crit. Rev. Toxicol. Vol. 28, pp 73-101.

• Chan P., DeLanney L.E., Irwin I., Langston J.W., Di Monte D., 1991. Rapid ATP loss caused by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J.

Neurochem. Vol. 57, pp 348-351.

• Chiba K., Trevor A., Castagnoli N. Jr, 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun.

Vol. 120, pp 1228-1232.

• Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Jacobowitz, Kopin I.J., 1984. Neurochemical and behavioural effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig and monkey.

Psychopharm. Bull. Vol. 20, pp 548-553.

(3)

• Corsini G.U., Pintus S., Chiueh C.C., Weiss J.F., Kopin I.J., 1985. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pre- treatment with diethyldithiocarbamate. Eur. J. Pharmacol.

Vol. 119, pp 127-128.

• Corsini G.U., Zuddas A., Bonuccelli U., Schinelli S., Kopin I.J., 1987. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sci. Vol. 40, pp 827-832.

• Dauer W. and Przedborski S., 2003. Parkinson’s disease.

Mechanisms and models. Neuron Vol. 39, pp 889-909.

• Davis C.G., Williams A.C., Markey S.P., Ebert M.H., Calne E.D., Reichert C.M., Kopin I.J., 1979. chronic parkinsonism secondary to intravenous injection of mepiridine analogues. Psychiatry Res. Vol. 1, pp 249-254.

• Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y.,

Jenner P., Marsden C.D., 1989. Increased nigral iron

content and alterations in other metal ions occutring in

brain in Parkinson’s desease. J. Neurochem. Vol. 52, pp

1830-1836.

(4)

• Donaldson J., McGregor D., LaBella F., 1982. Manganese neurotoxicity: a model for free radical mediated neurodegeneration? Can. J. Phisiol. Pharmacol. Vol. 60, pp 1398-1405.

• Fabre E., Monserrat J., Herrero A., Barja G., Leret M.L., 1999. Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum. J. Physiol. Biochem. Vol. 55, pp 325-331.

• Forno L.S., Langston J.W., De Lanney L.E., Irwin I., Ricaurte G.A., 1986. Locus Coeruleus lesions and eosinophilic inclusion in MPTP-treated monkeys. Ann.

Neurol. Vol. 20, pp 449-455.

• Halliwell B., 1992. Reactive oxygen species and the central nervous system. J. Neurochem. Vol. 59, pp 1609- 1623.

• Halliwell B., Gutteridge J.M.C., 1984. Oxygen toxicity, oxygen radicals, transition metals and disease. J. Biochem.

Vol. 219, pp 1-14.

• Hallman H., Lange J., Olson L., Stromberg I., Jonsson

G.m 1985. Neurochemical and histochemical

characterization of neurotoxic effects of 1-methyl-4-

(5)

phenyl-1,2,3,6-tetrahydropyridine (MPTP) on brain catecholamine neurons in the mouse. J.Neurochem. Vol.

44, pp 117-127.

• Hansson T., Tindberg N., Ingelman-Sundberg M., Kohler C., 1990. Regional distribution of ethanol-inducible cytochrome P450 2E1 in the rat central nervous system.

Neuroscience Vol. 34, pp 451-463.

• Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C., 1984. Protection against the dopaminergic neurotoxicity of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature Vol. 331, pp 467- 469.

• Irwin I., Langston J.W., DeLanney L.E., 1987a. 4- phenylpyridine (4PP) and (MPTP): The relationship between striatal MPP+ concentrations and neurotoxicity.

Life Sci. Vol. 40, pp 731.

• Irwin I., Wu E.Y., DeLanney L.E., Trevor L., Langston

J.W., 1987b. The effect of diethyldithiocarbamate on the

biodisposition of MPTP: an explanation for enhanced

neurotoxicity. Eur. J. Pharmacol. Vol. 141, pp 209-217.

(6)

• Iscan M., Reuhl K., Weiss B., Maines M.D., 1990.

Regional and subcellular distribution of cytochrome P450- dependent drug metabolism in monkey brain: the olfactory bulb and the mitochondrial fraction have high levels of activity. Biochem. Biophys. Res. Commun. Vol. 169, pp 858-863.

• Javitch J.A., D’Amato R.J., Strittmatter S.M., Snyder S.H., 1985. Parkinsonism-inducing neurotoxin, N-methyl-4- phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc. Natl. Acad. Sci.

USA Vol. 82, pp 2173-2177.

• Jenner P., 1998. Oxidative mechanisms in nigral cell death in Parkinson’s desease. Mov. Disord. Vol. 13 suppl., pp 24-34.

• Langston J.W., Ballard P., Irwin I., 1983. Chronic parkinsonism in humans due to a product of meperidine- analog synthesis. Science Vol. 219, pp 979-980.

• Langston J.W., Irwin I., Langston E.B., Forno L.S., 1984.

Pargyline prevents MPTP-induced parkinsonism in

primates. Science Vol. 225, pp 1480-1482.

(7)

• Lau Y.S., Trobough K.L., Crampton J.M., Wilson J.A., 1990. Effects of prebenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6- tetrahydropiridine (MPTP)-treated mice. Gen. Pharmacol.

Vol. 21, pp 181-187.

• Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., Gonzales F.J., 1996. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. Vol. 271, pp 12063- 12067.

• Lestienne P., Nelson I., Riederer P., Jellinger K., Reichmann H., 1990. Normal mitochondrial genome in brain from patients with Parkinson’s Desease and complex I defect. J. Neurochem. Vol. 55, pp 1810-1812.

• Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J., 1951. Protein measurement with the folin phenol reagent.

J. Biol. Chem. Vol. 193, pp 265-275.

• Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S.,

Herkenham M.A., 1984. Intraneuronal generation of a

pyridinium metabolite may cause drug-induced

parkinsonism. Nature Vol. 11, pp 464-467.

(8)

• Mayer R.A., Kindt M.V., Heikkila R.E., 1986. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by inhibitors of 3,4- dihydroxyphenylthylamine transport. J. Neurochem. Vol.

47, pp 1073-1079.

• McGrew D.M., Irwin I., Langston J.W., 2000.

Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice. Neurotoxicology Vol.

21, pp 309-312.

• Miller D.B., Reinhard J.F., Daniels A.J., O’Callaghan J.P., 1991. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo MPTP and in vitro MPP

⁺

. J. Neurochem. Vol.

57, pp 541-549.

• Nicklas W.J., Vyas I., Heikkila R.E., 1985. Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci. Vol. 36, pp 2503-2508.

• Nissbrandt H., Bergquist F., Jonason J., 2001. Inhibition of

cytocrome P450 2E1 induces an increase in extracellular

dopamine in rat substantia nigra: a new metabolic

pathway? Synapse Vol. 40, pp 294-301.

(9)

• Norman B.J., Neal R.A., 1976. Examination of the metabolism in vitro of parathion (diethyl p-nitrophenyl phosphorothionate) by rat lung and brain. Biochem.

Pharmacol. Vol. 25, pp 37-45.

• Pileblad E., Carlsson A., 1985. Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) in mouse brain.

Neuropharmacology Vol. 24, pp 689-692.

• Ramsay R.R., Singer T.P., 1986. Energy dependent uptake of N-methyl-4-phenylpyridinium the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by mitochondria. J. Biol. Chem. Vol.

261, pp 7585-7587.

• Ravindranath V., Anandatheerthavarada H.K., Shankar S.K., 1989. Xenobiotic metabolism in human brain-- presence of cytochrome P-450 and associated mono- oxygenases. Brain Res. Vol. 496, pp 331-335.

• Ricaurte G.A., Langston J.W., DeLannery L.E., Irwin I.

Brooks J.D., 1985. Dopamine uptake blockers protect

against the dopamine depleting effect of 1-methyl-4-

phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse

(10)

• Ricaurte G.A., Langston J.W., DeLannery L.E., Irwin I., Peroutka S.J., Forno L.S., 1986. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. Vol. 376, pp 117- 124.

• Sanchez-Ramos J.R., Michel P., Weiner W.J., Hefti F., 1988. selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4- phenylpyridinium: Cytochemical and morphological evidence. J. Neurochem. Vol. 50, pp 1934-1944.

• Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clarck J.B., Marsden C.D., 1990. Mitochondrial complex I deficiency in Parkinson’s disease. J. Neurochem. Vol. 54, pp 823-827.

• Schlinger B.A., Callard G.V., 1989. Localization of aromatase in synaptosomal and microsomal subfractions of quail (Coturnix coturnix japonica) brain.

Neuroendocrinology Vol. 49, pp 434-441.

• Stokes A.H., Hastings T.G., Vrana K.E., 1999. Cytotoxic

and Genotoxic Potential of Dopamine. J. Neurosc. Vol. 55,

pp 659-665.

(11)

• Stott I., Murthy A., Robinson A., Thomas N.W., Fry J.R., 1997. Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat. Hum. Exp. Toxicol.

Vol. 16, pp 262-266.

• Sundstrom E., Goldstein M., Jonsson G., 1985.

Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Eur. J.

Pharmacol. Vol. 110, pp 293-299.

• Takahashi R.N., Rogerio R., Zanin M., 1989. Maneb enhances MPTP neurotoxicity in mice. Res. Com. Chem.

Pathol. Pharmacol. Vol. 66, pp 167-170.

• Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., Cory-Slechta D.A., 2003. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype. Eur. J.

Neurosci. Vol. 18, pp 589-600.

• Tindberg N., Ingelman-Sundberg M., 1996. Expression,

Catalytic Activity, and Inducibility of Cytocromo P450

(12)

2E1 (CYP 2E1) in the Rat Central Nervous System. J.

Neurochem. Vol. 67, pp 2066-2073.

• Vaccari A., Saba P.L., Ruiu S., Collu M., Devoto P., 1996.

Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol. Appl.

Pharmacol. Vol. 139, pp 102-108.

• Vaglini F., Fascetti F., Tedeschi D., Cavalletti M., Fornai F., Corsini G.U., 1996. Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration Vol. 5, pp 129-136.

• Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., Corsini G.U., 2004. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced mouse model of Parkinson’s desease. J.

Neurochem. Vol. 91, pp285-298.

• Walters T.L., Irwin I., Delfini K., Langston J.W., Janson A.M., 1999. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP.

Exp. Neurol. Vol. 156, pp 62-70.

(13)

• Warner M., Wyss A., Yoshida S., Gustafsson J.Å., 1994.

Cytochrome P450 enzymes in brain. Methods in Neurosciences, vol. XXII. Academic Press, New York, pp 51-66.

• Watts P.M., Riedl A.G., Douek D.C., Edwards R.J., Boobis A.R., Jenner P., Marsden C.D., 1998. Co- localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neurosc. Vol. 86, pp 511-519.

• Youdim M.B.H, 1988. Iron in the brain: implication for Parkinson’s and Alzheimer’s diseases. Mount. Sinai J.